Q-omics provides the consensus-scored RASL10A profile across patient tissues and cancer cell-line models. RASL10A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RASL10A is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, RASL10A RNA expression shows 16,755 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, KIRC, and UVM as cancer lineages where RASL10A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RASL10A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RASL10A survival associations across molecular data types. RASL10A RNA expression shows survival associations in the most cancer types (24), followed by mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RASL10A RNA expression–survival associations across cancer types. High RASL10A expression shows unfavorable associations in MESO, ACC, OV and UVM, but favorable associations in PAAD and LGG. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for RASL10A RNA expression.
This table summarizes RASL10A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RASL10A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RASL10A shows lower tumor expression in BRCA, LUAD and KIRP and higher tumor expression in KIRC, BLCA and STAD. The KIRC box plot shows higher RASL10A RNA expression in tumor versus normal tissue (log2 FC = +0.420, t-test p < 0.001).
This table shows molecular features associated with RASL10A in patient tissues and cancer cell lines. In patient samples, RASL10A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RASL10A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SOFT_TISSUE.
